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Rates of Use 
 Smokeless tobacco is defined as any form of nicotine-containing tobacco that is either 
chewed or snuffed rather than smoked by the user. In contrast to declining rates of cigarette use 
in the United States (US), sales and consumption of smokeless tobacco (ST) have continued to 
increase.1,2  As of 2016, it was estimated that up to 6.6% of US men, 0.5% of US women and 5.5% 
of high school students use ST.3  These rates have increased substantially from the year 2000 
when only 4.4% of US men and 0.3% of US women were reported to use ST.4 Additionally, many 
cigarette manufacturers have begun producing ST and are marketing it as a less harmful 
alternative to cigarette use which leads to a concern for dual consumption of both nicotine-
containing products.2 Many studies in the US have reported a moderate to strong degree of 
association between current smoking and use of ST.4  
 
Adverse Effects of Smokeless Tobacco 
 Although ST is considered less dangerous than cigarettes and other smoked tobacco 
products, ST use continues to be associated with many poor health outcomes worldwide.2,5  In 
the US, its use can lead to nicotine addiction, periodontal disease, cancer and precancerous oral 
lesions, pancreatic cancer, early parturition, stillbirth, childhood poisoning, hypertension and 
death from heart disease and stroke.2,4,6  Twenty-eight carcinogens have been identified in ST; 
the most abundant group of carcinogens are the non-volatile alkaloid derived tobacco-specific N-
nitrosamines and N-nitrosamino acids.4 Smokeless tobacco acts as an autonomic and 
hemodynamic stimulus by increasing heart rate, blood pressure and epinephrine levels.2 Some 
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studies have even found the effect on heart rate and blood pressure to be more severe in ST use 
than in cigarette use.7 Smokeless tobacco products used in the US have a uniquely increased risk 
of fatal myocardial infarction and fatal stroke when compared to ST from other countries.8  
Overall ST has fewer and less severe adverse health outcomes than cigarette smoking;2 however, 
considering the growing rate of ST consumption, health care providers are faced with a difficult 
task of providing support for their patients who would benefit from ST cessation.   
 
Current Smokeless Tobacco Cessation Recommendations 
 Despite the increasing rates of ST consumption and the numerous adverse health 
consequences, medical and oral health professionals in the US have a lack of evidence-based 
guidelines to assist them in providing effective treatment for ST use.2  Currently, the U.S. Food 
and Drug Administration has not approved any cessation products specifically for the treatment 
of tobacco dependence in ST users.  The World Health Organization (WHO) Framework 
Convention on Tobacco Control (FCTC) is a treaty developed by the UN to reduce tobacco use. 
Unfortunately, this treaty mainly focuses on smoking cessation and does not differentiate 
between cigarette and ST use.5  In England, ST cessation guidelines for health professionals were 
published in 2004. However, ST is used in the UK predominantly by members of the Indian, 
Pakistani, and Bangladeshi communities. The most commonly used form of ST in this population 
is called “quid” and has been found to have different physiological and adverse health effects 
than the ST used in the US.9   
There are more than 40 different types of ST products consumed around the world.4 The 
type of tobacco used is geographically determined. In the US, the principal types of ST are snus 
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(moist ground tobacco) and chewing tobacco (cut tobacco leaves).2,10 The type of tobacco used 
in a particular product has an influence on its pharmacodynamics, pharmacokinetics, sensory and 
behavioral involvements, adverse health outcomes, dependence patterns, and potential 
responses to cessation methods.2,4,8,10  
The three main cigarette cessation methods used in the US include nicotine replacement 
therapy (NRT), non-nicotine pharmacotherapies (varenicline and bupropion) and behavioral 
therapies. Smokeless tobacco specific recommendations are not currently available for health 
care providers in the US.  This article examines whether the listed cigarette cessation methods 
are equally effective in reaching long-term abstinence rates when used by ST users, for which 
long-term abstinence is defined as zero ST consumption for 6 months or more.  
 
COMPARING SMOKLESS TOBACCO AND CIGARETTES 
Absorption and Distribution 
 There are many factors that determine the pharmacokinetics and pharmacodynamics of 
nicotine-containing products. The route of administration is one of the most important factors 
when evaluating a tobacco product’s effects, especially when considering absorption.4,10  
Significant differences between nicotine absorption rates from smoked tobacco versus ST 
products have been well-documented.4 It has been postulated that these differences among 
nicotine products may determine the dependence patterns and response to cessation 
methods.10  
Multiple studies have shown that nicotine absorption and therefore nicotine-dosing 
capability varies between products.4,7 The difference in nicotine absorption from ST use versus 
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cigarette use is determined primarily by nicotine content and amount and frequency of use.4 One 
study analyzed 17 brands of ST in the US and found that the nicotine content ranged anywhere 
from 0.47% dry weight to 3.34% dry weight.4 Comparatively, the average Marlboro Light’s® 
nicotine content is approximately 2.09% of dry weight.11  Although the nicotine content is quite 
similar between ST and cigarette products, the amount and frequency of use differ greatly. 
Duration of use of ST is approximately 20-40 minutes whereas the duration of cigarette use is 
approximately 5-7 minutes.10 For this reason, those who use ST are exposed to nicotine for longer 
periods of time and are therefore absorbing a higher level of nicotine content overall.  
Additionally, absorption kinetics of ST differ greatly from cigarettes.10  Absorption of 
nicotine from smoking occurs rapidly through the pulmonary circulation; peak blood levels are 
achieved quickly.10,12  Nicotine levels then decline rapidly once the cigarette is finished.12 
Comparatively, absorption of nicotine from ST occurs through mucous membranes and thus 
declines at a much slower rate. 10,12  One study proposes that nicotine from ST continues to 
absorb into systemic circulation even after the product is removed from the mouth. It is 
suggested that the continued absorption is due to a slow release of nicotine from mucous 
membranes as well as from nicotine that has been swallowed. For these reasons, overall 
absorption of nicotine is twice as great from ST when compared to cigarettes.12 
These differences in absorption lead to distinctive cardiovascular effects and dependence 
patterns.12  Absorption of nicotine from cigarette use occurs as arterial boluses resulting in 
significant peaks and valleys in the nicotine concentration with each puff from a cigarette. These 
peaks and valleys in nicotine concentration are not observed in those who use ST.10  The slower 
absorption of nicotine from ST use, consequently allows the central nervous system to be 
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presented with a steadier rate of nicotine distribution as opposed to the pulsed increases seen 
with cigarette use. The magnitude of cardiovascular response is correlated directly with the rate 
of decline in nicotine blood levels. Heart rate and blood pressure remain elevated for longer 
periods of time in ST users than in cigarette users resulting in a greater overall cardiovascular 
effect from ST use. 7,12  Additionally, the propensity towards tobacco addiction is associated with 
the rate at which nicotine is distributed to the CNS along with the behavioral and sensory stimuli 
that accompany tobacco use.10,12 
 
Sensory and Behavioral Involvement 
 Repeated use of tobacco products is related to nicotine as well as non-nicotine factors. 
Sensory stimulation and behaviors that accompany ST use differ from those associated with 
cigarette smoking.  Sensory stimulation from cigarette use is considered very rich, involving 
factors such as visual smoke, taste, smell, and impact on throat and airways. It is often used as a 
social element as a form of bonding. On the other hand, sensory stimuli from ST  is associated 
more with taste, smell, sucking, chewing, as well as pressure and a burning sensation on the 
mucosa where the product is placed.10  These sensory and behavioral differences among 
nicotine-containing products may reflect the differences in response to cessation methods.  
 
EFFICACY OF CESSATION METHODS 
Nicotine Replacement Therapy 
 Nicotine replacement therapy (NRT) consists of products designed to deliver nicotine to 
the body in a form that does not involve smoking or the ingestion of any tobacco-containing 
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products. It comes in 16-hour and 24-hour transdermal patches, 2 or 4 mg chewing gum, and 1, 
1.5, 2, and 4 mg nicotine lozenges, among other formulations. The goals of NRT are to reduce 
withdrawal symptoms and to provide a coping mechanism, making tobacco products less 
rewarding.13  
 Many studies support the use of NRT for cigarette cessation; it is considered a first-line 
treatment modality for anyone who wants to quit smoking.5,14,15,16  Conversely similar evidence 
supporting the use of NRT in ST cessation is lacking. In cigarette users, NRT is found to reduce 
withdrawal symptoms and therefore increase abstinence rates.14 When used by those who 
consume ST, a reduction in withdrawal symptoms is also observed. However, despite the 
reduction in withdrawal symptoms, abstinence rates do not improve when compared to 
placebo.14  This failure contradicts the premise that nicotine replacement is the primary 
mechanism of action for achieving abstinence from tobacco. In most studies, NRT has not been 
found to increase abstinence rates for ST users regardless of formulation or dose.2,5,14  Nicotine 
gum may, in fact, facilitate lapse or relapse in ST use.14 One study that examined the use of NRT 
in ST cessation did find a potential benefit for use of lozenges when combined with coach calls.1 
The evidence from this study suggests that the lozenges initially helped participants with 
withdrawal symptoms and the coach calls provided social support for continued abstinence 
which allowed the combination to be more successful than either coach calls or lozenges alone. 
Unfortunately, this study is flawed in that it did not use biochemical validation of abstinence, 
hence possibly overestimating true cessation rates.  
NRT may not be as successful in ST cessation when compared with cigarette cessation for 
several reasons. Smokeless tobacco delivers a higher overall nicotine concentration than 
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cigarettes. The dosage of nicotine provided in NRT may be too low for ST users. Additionally, 
there are similarities in the behavior (sucking and chewing), the rate of absorption and the 
distribution patterns of oral NRT and ST. Due to the behavioral similarities of using ST and oral 
NRT in addition to the initial alleviation of withdrawal symptoms, it’s possible that oral NRT 
products produce a priming effect that facilitates relapse and that ST users do not effectively 
learn new behavioral or coping skills that would substitute for ST use.  
  
Bupropion 
 Bupropion is an atypical antidepressant that has multiple actions in the brain involving 
dopamine and noradrenaline pathways and is a non-competitive nicotine receptor antagonist. It 
is also believed to inhibit the firing of adrenergic neurons in the locus coeruleus which is the 
region of the brain responsible for the stress and panic associated with withdrawal from nicotine. 
A typical course for cigarette cessation is 300 mg per day for 7-8 weeks, beginning a week prior 
to the designated quit date.17 
 In cigarette users, bupropion is generally considered as effective as NRT in achieving long 
term abstinence rates.5,16  One study showed bupropion increases abstinence rates in cigarette 
users by 7% when compared to placebo.5 Although other studies have mixed results, it is still 
considered a first-line pharmacotherapy for smoking cessation.  In ST users, however, bupropion 
has not been shown to be effective in reaching long term abstinence rates.2,5 It is important to 
note that bupropion has not been studied without the use of behavioral support.5 
 It is possible that bupropion is less effective in ST users than in cigarette users due to the 
differences in the absorption and distribution characteristics of these products. Smokeless 
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tobacco users are exposed to nicotine for longer periods of time leading to a more constant 
plasma level than those who smoke cigarettes. With a more constant and extended nicotine 
plasma level, compared to cigarette users, ST users may have a lower adrenergic reserve available 
for the bupropion’s action. It is this adrenergic response in the locus coeruleus that is believed to 
be responsible for withdrawal symptoms. With cigarette use, there is sufficient time between 
nicotine dosing periods to rebuild the adrenergic reserve. Therefore, in cigarette users, the 
bupropion has the opportunity to attenuate the effects of the adrenergic response and reduce 
the withdrawal symptoms. It’s also possible that the constant nicotine levels in ST may 
desensitize nicotine receptors making them unavailable to bupropion. In cigarette users, 
however, the lack of constant stimulus by nicotine may actually prevent desensitization of the 
nicotine receptors allowing the bupropion to be more effective.  
 
Varenicline 
 Varenicline is a partial agonist designed to bind with high affinity to the alpha-4 beta-2 
subunits of nicotine receptors where its binding produces agonist activity while simultaneously 
preventing nicotine from binding to these receptors. Through these actions, varenicline is 
believed to reduce symptoms of nicotine withdrawal and reduce the rewarding aspects of 
tobacco use.18 A standard course of treatment for cigarette cessation is 1 mg per day beginning 
1 week before the designated quit date then 11 weeks at 2 mg per day. 
 Varenicline is generally considered one of the most effective tobacco cessation 
products.16 In cigarette smokers, varenicline has been found to increase abstinence rates by 
131% when compared to placebo. In ST users, however, it does not appear to be as effective. The 
 9 
evidence from the same study showed that varenicline only increased long term abstinence rates 
by 34% when compared to placebo.2  Although it may not be as effective in reaching long term 
abstinence in ST users, it does increase the likelihood of recovery after a lapse.19 As with 
bupropion, all varenicline studies involved some form of behavioral support.5 
 The peaks and valleys in nicotine concentration observed in cigarette users are not 
observed in ST users. This difference may explain why varenicline is less effective in ST cessation 
than in cigarette cessation. Varenicline is a partial agonist which binds to the same receptors as 
nicotine consequently preventing the nicotine molecule from binding. In ST, the higher nicotine 
concentration may lead to greater occupancy or desensitization of the nicotine receptors and 
therefore may not allow the varenicline molecule the opportunity to bind. On the other hand, 
the valleys in nicotine concentration observed in cigarette use may allow opportunity for the 




 A wide variety of behavioral interventions for the treatment of tobacco cessation is 
available. Some more widely accepted options include brief advice and face-to-face behavioral 
support. Brief advice involves a health-care worker raising the topic of smoking or ST use with a 
patient, advising the patient to stop and/or offering support and follow up. Face-to-face 
behavioral support, on the other hand, is a bit more intensive. It may include advice, discussions, 
encouragement or activities designed to assist in the cessation of tobacco and may be delivered 
 10 
individually or in groups. Other behavioral interventions may include printed self-help materials, 
automated text messages, telephone counseling, oral examination and interactive websites.  
 It is difficult to directly compare behavioral interventions because the components of 
interventions that contribute to their impact are not clear.2 In general, behavioral interventions 
vary with efficacy in abstinence rates.2  Evidence mainly supports using some form of behavioral 
intervention regardless of the use of pharmacotherapy.16 Even brief advice from a health-care 
worker, compared to doing nothing, has been found to promote smoking cessation and increase 
abstinence rates of cigarette users by 2%.5 However, insufficient evidence prevents conclusions 
about brief advice to promote ST cessation.5  Face-to-face behavioral support has been found to 
be effective in both cigarette and ST users.5 Behavioral interventions incorporating telephone 
support and oral examination also appear to be effective in reaching long term abstinence in ST 
users.2  
 It is unclear whether behavioral interventions alone are more successful when used in 
cigarette smokers compared to ST users. Regardless of the tobacco product being used, 
behavioral intervention appears to play an important role in reaching long term abstinence rates. 
Nicotine itself is a weak reinforcer but becomes stronger when the drug is paired with 
environmental cues. These reasons likely explain why behavioral intervention plays such an 
important role in the cessation of all nicotine-containing products. While pharmacotherapy may 
assist with the physiological symptoms of withdrawal, behavioral interventions provide the social 
support for patients to help them identify and challenge the environmental cues that trigger 




If the cessation methods are ranked from the most to the least successful, the list would 
be in the same order for both ST and cigarette use. However, the likelihood of each of these 
cessation methods achieving long term abstinence rates appears to be higher in cigarette users 
than in ST users overall. Furthermore, it is unclear if NRT and bupropion are effective at all in ST 
cessation. In fact, it’s possible that NRT may actually promote relapse in ST users. In cases where 
NRT was found to be effective, it was combined with behavioral interventions. Varenicline 
appears to be the most effective pharmacotherapy for the treatment of ST dependence; 
however, it too must be combined with behavioral interventions to achieve the best results. 
Regardless of the cessation method used, it is important to consider using some form of 
behavioral intervention as it appears to increase abstinence rates in both ST and cigarette users.  
Currently, healthcare providers in the US make the same recommendations for cessation 
of both ST and cigarette use. The conclusions derived from the evidence in these studies do not 
necessarily change the recommendations that providers will give to their patients. The findings 
should, however, make clinician expectations of patients’ success more realistic when using 
cigarette cessation methods in ST users.  
 
IMPLICATIONS FOR FURTHER RESEARCH 
 More research is necessary to determine the most effective way for ST users to achieve 
long term abstinence rates. Since, compared to cigarette use, ST use leads to more sustained and 
higher nicotine levels through its continuous absorption, determining the most effective NRT 
dose, formulation, and duration of therapy is necessary.  Additionally, many studies support the 
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use of NRT combined with non-NRT pharmacotherapies for cigarette cessation, whereas research 
on this combination therapy in ST cessation is lacking, but would be beneficial.  
Due to the differences in nicotine plasma concentrations between ST and cigarette users, 
the possibility that non-NRT pharmacotherapies would be more effective if initiated after the 
patient has discontinued ST for a short period should be explored. In these proposed studies, the 
patient may achieve an initial discontinuation phase by using NRT, which may lower the plasma 
concentration of nicotine, allowing for the non-NRT pharmacotherapies to be more effective.  
Starting varenicline after an initial discontinuation phase may allow better binding between 
varenicline and the nicotine receptors. Analogously, starting bupropion after an initial 
discontinuation phase may allow either the adrenergic reserve to restore or permit receptor 
sensitization to return, giving bupropion the opportunity to have a more robust effect on the 
withdrawal symptoms.  
Lastly, behavioral intervention methods and efficacies vary widely. Future research 
should aim at identifying the most effective core components of behavioral interventions for the 
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